Japan to send anti-flu drug Avigan to Philippines, 42 other countries for coronavirus research

Kyodo News

<div class="embed-wrap"><figure data-feedback="fb:likes,fb:comments"><img src="http://sa.kapamilya.com/absnews/abscbnnews/media/2020/reuters/05/01/20200405-avigan.jpg"/><figcaption>Tablets of Avigan (generic name: Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm&#x27;s headquarters in Tokyo, Oct. 22, 2014. Issei Kato, Reuters/File</figcaption></figure></div>TOKYO - Japan will provide anti-flu drug Avigan free of charge to 43 countries for clinical studies on its efficacy as a coronavirus treatment, Foreign Minister Toshimitsu Motegi said Friday.The drug is expected to be sent after the Golden Week holidays through May 6, Motegi said, a delay to his earlier projection that shipments could begin this week.Some 80 countries have shown interest in Avigan, with Motegi previously saying arrangements have been made to send it to 38. Bangladesh, the Dominican Republic, Laos, Qatar and Uzbekistan have since been added to the list of recipients, according to the Foreign Ministry.Japan is paying for the initiative through a $1 million grant to the United Nations Office for Project Services, which will buy and distribute the drug.Each country will receive enough to treat between 20 and 100 people for research purposes, Motegi said.&quot;We will cooperate with the private sector as well as the international community to develop a treatment&quot; for coronavirus, he told a press conference.Kyodo <a href="https://english.kyodonews.net/news/2020/04/01f746e01617-japan-to-offer-anti-flu-avigan-to-38-countries-as-early-as-this-week.html">earlier reported</a> that among the recipients are 25 European countries, mostly from Eastern Europe, six in Asia including the Philippines and Malaysia, five in the Middle East such as Kuwait, and two from other regions, according to the Foreign Ministry.Japan has been conducting clinical studies into Avigan after Chinese scientists suggested it had been effective in treating COVID-19 patients, especially those with mild symptoms.The drug, also known as favipiravir, was developed by a subsidiary of Fujifilm Holdings Corp.Japan plans to triple its stockpile of Avigan, enough to treat 2 million people, while China has said it will officially adopt it as part of its treatment guidelines for coronavirus.As the drug is feared to cause birth defects, it cannot be used on pregnant women.

Japan will provide anti-flu drug Avigan free of charge to 43 countries for clinical studies on its efficacy as a coronavirus treatment, Foreign Minister Toshimitsu Motegi said Friday.

Japan will provide anti-flu drug Avigan free of charge to 43 countries for clinical studies on its efficacy as a coronavirus treatment, Foreign Minister Toshimitsu Motegi said Friday.

Japan to send anti-flu drug Avigan to Philippines, 42 other countries for coronavirus research | ABS-CBN

Halalan 2025

Entertainment

News

Metro.Style

Lifestyle

Sports

More

Traffic

Horoscope

Overseas

Japan to send anti-flu drug Avigan to Philippines, 42 other countries for coronavirus research

Japan to send anti-flu drug Avigan to Philippines, 42 other countries for coronavirus research

Kyodo News

Published May 01, 2020 05:05 PM PHT

Read More:

Japan

Tokyo

Avigan

anti-flu drug

treatment

cure

antidote

health

virus

coronavirus

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

AI Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Privacy Policy

Terms of Service

AI Policy

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.